On Jun. 8, 2021, Inovio Pharma announced an expansion of its previously announced partnership with Advaccine Biopharmaceuticals to jointly conduct a global Phase 3 segment of the ongoing Phase 2/3 trial called INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy).

The primary endpoint of the Phase 3 segment was virologically confirmed COVID-19 disease. The 2.0 mg dose was selected from the Phase 2 segment, where INO-4800 was shown to be generally well-tolerated and immunogenic in all tested age groups.